



## **Reserves**

The Company has not transferred any amount to reserves during the F.Y. ended on 31st March, 2021.

## **Dividend**

The Board of Directors have not recommended any dividend for the Financial Year ended on 31<sup>st</sup> March, 2021.

## **Brief description of the Company's working during the year**

### **Procurement of Drugs/ Medicines and Surgical & Sutures**

- ❖ Corporation engaged in procurement of quality generic drugs, surgical and sutures and other hospital supplies for onward supply to public health institutions viz. Medical College Hospitals, District Hospitals, Sub-divisional Hospitals, Satellite Hospitals, CHCs and PHCs for further distribution free of cost to all patients visiting public health institutions of the State.
- ❖ As on 31st March, 2021, the Essential Drug List (EDL) of RMSCL comprises of 713 drugs and 181 surgical & 77 sutures.
- ❖ During the year, 03 new drugs namely Inj. IgM enriched IVIG, Tab Dasatinib 100 mg & Liquid Medical Oxygen (LMO) were added in Essential Drug List (EDL) of RMSCL. LMO was added with an aim to provide immediate relief towards prevailing shortage of oxygen for COVID-19 patients.
- ❖ During the year, Corporation has procured and supplied various covid-19 medicines and items like VTM Kit, PPE Kit, N-95 Mask, Sodium Hypochloride, Hand Rub (Sanitizer), Triple layer Mask, Nitrile gloves, Dead Body Bag, Air Tight goggles, Autoclaveable Poly bags, Infrared Thermometer, Shoe covers, PCR machines, Ultrashield, Vertical autoclave, water proof jump suit, Inj. Remdesivir, Inj. Tocilizumab, Lopinavir 200 mg+ Ritonavir 50mg tablet etc. related to prevention of spread of Coronavirus (Covid-19).
- ❖ Demand for all Covid-19 medicines like Inj. Remdesivir, Inj. Tocilizumab and items like N95, VTM Kit, Hand sanitizer, Nitrile Gloves, Sodium Hypochlorite, Triple Layer masks etc. was compiled from Medical & Health Department and Medical Education Department and accordingly procurement has been done.
- ❖ During the period under review, Inj. Remdesivir 100mg essential for treatment of coronavirus (Covid-19) was also provided to private hospitals. During the first wave of covid-19, there was adequate quantity of covid-19 drugs and items available with RMSCL.
- ❖ At the end of financial year, the corporation has rate contract of around 639 drugs and 75 surgical sutures out of 713 drugs and 258 surgical sutures included in EDL.

### **Quality Control**

- ❖ The Company has its Quality Control Policy and procedures for ensuring quality of drugs, surgical



and sutures supplied by firms/ companies and has made guidelines for blacklisting/ debarring of products or company on various grounds.

- ❖ The drugs are issued to public health institutions, when it passes all the specified quality tests and are found as of standard quality. The rejected drugs even if it fails on account of minor reason, are returned to the manufacture.

During the year, test reports of 11857 drug samples were received from empanelled laboratories of RMSCL and out of them 179 batches have been rejected due to Not of Standard Quality (NOSQ) and physical defects. Percentage of failure of drugs during the year was 1.51%. During F.Y. 2020-21, 09 laboratories were empanelled by company for testing of drugs.

### **Storage**

The corporation has 34 District Drug Warehouses (DDWs) in every District of Rajasthan for storage as per norms and speedy movement of drugs/surgical /sutures to public health institutions and 06 Medical College Drug Warehouses (MCDWs) at Ajmer, Bikaner, Jodhpur, Kota, Udaipur and Jaipur to cater the need of hospitals attached to Medical Colleges. During the year, regular upkeep and maintenance of cold chain systems and infrastructure / equipments of the warehouses was undertaken.

### **Procurement and Maintenance of Equipment & Instruments**

- ❖ Corporation procures equipment and other hospital supplies for Medical, Health and Family Welfare Department, Medical Education Department, NHM and other Public Health Institutions as per the demand received from them. Rate contracts are executed by Corporation with successful bidders through e-bidding in a very transparent manner for supply of equipment, instrument and other hospital supplies.
- ❖ During the year, Corporation has successfully monitored the work of repair and maintenance of 147 type of Bio-Medical Equipment through e-Upkaran software. These equipments have installed up to PHC and Sub Center level. This has helped in successful running of 'Mukhyamantri Nishulak Janch Yojana' programme of State Government.
- ❖ The Corporation is also using e-TMTS (electronic- tender management and tracking system) Software for monitoring and tracking of bids of equipment and instruments. This software is useful for generation of reports related to number of RC's, bids floated, current stage of bids, generation of demand, issue of proforma invoice and purchase orders, timely payment to the suppliers, reply to the letters of suppliers etc. This software has been upgraded and by up gradation of this software, status of all stages of procurement process i.e. receipt of A&F (initial state of procurement process) till the issue the Utilization Certificate to concerning department can be monitored through this software.

### **On line Transactions**

The Corporation has been carrying out most of its activities especially relating to inventory management





through online web based e-Aushadhi software. This application has various modules like Annual demand generation, Rate Contract, Purchase Order generation, Challan process, Quality Control, Issue & Return, Supplier interface, Lab Interface and various kinds of reports, which facilitate management of drugs availability.

This software includes all the processes required for smooth operation of "MNDY". The software also provides all the reports which are required for decision making for higher level management. Every year new modules are added in e-Aushadhi software as per requirement of the organization. During the year under review, following new modules/changes have been developed:

- **Supply schedule form for District Drug warehouse:** A new service is developed to insert supply schedule by district drug warehouse for issuance of drugs to sub store.
- **Auto Indent process for Sub store:** An automated indent process on specified schedule day (based on consumption) for indent drugs from sub store is developed.
- **Implementation of Auto Indent & Sub store:** Successfully Implemented auto indent facility to DDC and Sub stores.
- **Covid Information form:** An entry form is developed for getting information of covid patients.

## Resources

The Corporation receives grant/ funds from Government of Rajasthan for procurement of drugs, surgical and sutures under 'Free Drug Distribution Scheme of Government of Rajasthan'. During the year under review, Company has received funds of Rs. 462.71 Crore from Government of Rajasthan. Funds of Rs. 527.05 Crore have been received from National Health Mission for procurement of drugs, surgical & sutures. Further, funds of Rs. 139.44 crore has been received for procurement of Covid-19 items (drugs and consumables).

## Financial Performance

During the year, the Corporation purchased drugs, surgical, sutures and equipments worth Rs. 807.87 Crore as compared to that of Rs. 813.16 crore in previous year. Corporation procured drugs and consumables related to covid-19 (corona virus) worth Rs. 134.77 crore during the year. Drugs, surgical, sutures and equipment worth Rs. 833.41 Crore have been issued to the public health institutions of the State as against Rs. 840.28 Crore in previous year.

The Company has achieved profit before tax of Rs. 20.92 crore as compared to Rs. 11.54 Crore in previous year. The profit after tax for the year ended on 31st March, 2021 amounts to Rs. 9.36 Crore as against profit of Rs. 7.36 Crore for the previous year.

## Change in the nature of business, if any

There has been no change in the nature of business of the Company.



**Material Changes and commitments, if any, affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which financial year relate and the date of the report.**

There have been no material changes and commitments affecting the financial position of the Company between the end of the financial year and the date of this report.

**Share Capital**

There has been no change in the authorized and paid up share capital of the Company during Financial Year 2020-21. The Company has not done any buy back of shares during the year under review.

**Directors**

During the period under review, the following changes have taken place in the composition of the Board of Directors of the company:-

- The following were appointed as Directors on the Board of RMSCL:-

Sr. No.	Name of Directors	Designation	Date of Appointment
1	Shri Sharad Mehra	Director	07.05.2020
2	Shri Akhil Arora	Chairman	03.07.2020
3	Dr. Veena Pradhan	Director	03.07.2020
4	Smt. Hempushpa Sharma	Director	22.07.2020
5	Shri Siddharth Mahajan	Chairman	02.11.2020
6	Dr. Rajesh Sharma	Managing Director	04.11.2020
7	Dr. Laxman Singh Ola	Director	18.11.2020
8	Shri Alok Ranjan	Managing Director	01.12.2020
9	Shri Suresh Chand Gupta	Director	06.01.2021
10	Dr. Ravi Prakash Sharma	Director	06.01.2021

During the year, State Government has nominated Smt. Hempushpa Sharma, RAcS, Government of Rajasthan, Jaipur as Woman Director on the Board of Directors of Corporation w.e.f. 22.07.2020 vide Government of Rajasthan, Medical & Health (Gr-5) Department order dated 22.07.2020.

Shri Vaibhav Galriya (IAS), Director of the Company has been appointed as Chairman of RMSCL in place of Shri Siddharth Mahajan (IAS) w.e.f 20.09.2021. Smt. Anupama Jorwal (IAS) has been appointed as Managing Director of RMSCL in place of Shri Alok Ranjan (IAS) w.e.f 20.09.2021. Shri Ashutosh